Emerging data from the chronic kidney disease (CKD) field suggest that both iron deficiency and EPO lead to an up-regulated expression and concomitant cleavage of a phosphate-regulating hormone, fibroblast growth factor 23 (FGF23), another risk factor for mortality. The gene discussed is EPO; the disease is Iron deficiency anemia.